These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 24694017)

  • 1. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
    Abate-Daga D; Lagisetty KH; Tran E; Zheng Z; Gattinoni L; Yu Z; Burns WR; Miermont AM; Teper Y; Rudloff U; Restifo NP; Feldman SA; Rosenberg SA; Morgan RA
    Hum Gene Ther; 2014 Dec; 25(12):1003-12. PubMed ID: 24694017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered T cells for pancreatic cancer treatment.
    Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
    HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
    Hillerdal V; Ramachandran M; Leja J; Essand M
    BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.
    Shah Z; Tian L; Li Z; Jin L; Zhang J; Li Z; Barr T; Tang H; Feng M; Caligiuri MA; Yu J
    Cell Stem Cell; 2024 Jun; 31(6):803-817.e6. PubMed ID: 38663406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
    Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
    Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
    Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
    J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
    Zhao Y; Wang QJ; Yang S; Kochenderfer JN; Zheng Z; Zhong X; Sadelain M; Eshhar Z; Rosenberg SA; Morgan RA
    J Immunol; 2009 Nov; 183(9):5563-74. PubMed ID: 19843940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
    Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
    Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
    Sukumaran S; Watanabe N; Bajgain P; Raja K; Mohammed S; Fisher WE; Brenner MK; Leen AM; Vera JF
    Cancer Discov; 2018 Aug; 8(8):972-987. PubMed ID: 29880586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
    Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 18. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
    Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
    Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.
    Wente MN; Jain A; Kono E; Berberat PO; Giese T; Reber HA; Friess H; Büchler MW; Reiter RE; Hines OJ
    Pancreas; 2005 Aug; 31(2):119-25. PubMed ID: 16024997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.